Wedbush Reaffirms “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Wedbush restated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a research note issued to investors on Tuesday morning, RTT News reports. The firm currently has a $30.00 price objective on the stock, up from their prior price objective of $28.00. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings […]
More Stories
Vishal Sanghavi, Founder & CEO, JEH Aerospace, interviewing Atul Arya, Founder & CEO, Blackstraw AI
On why AI fails in production, what it actually takes to scale, and the work most companies avoid. Vishal Sanghavi...
How a Business Internet Provider Keeps Small Companies Connected
Small companies depend on internet access for payments, cloud applications, customer calls, file transfers, and daily coordination. A short outage...
How a Mortgage Marketing Agency Drives Leads for Lenders Online
Mortgage lenders compete for borrowers, who first research rates, loan types, and local providers online before contacting anyone. Visibility depends...
US Signs Critical Minerals, Energy, Technology Deals With Finland, Hungary
By Victoria Friedman The United States has signed critical mineral, energy, and technology deals with Finland and Hungary, strengthening economic...
Israel Heads for Coalition Talks After Election Deadlock
By Evgenia Filimianova Final Israeli election results showed that neither Prime Minister Benjamin Netanyahu nor his main rival, Gadi Eisenkot,...
Nasdaq Falls More Than 2 Percent as Amazon, Intel Earnings Weigh on Markets
By Andrew Moran The tech-heavy Nasdaq Composite Index fell more than 2 percent as disappointing results from Amazon and weak...